Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5807297 | 0.77 | CYP2C19 (0.40) | CYP2C19 | |
| SCHEMBL7703948 | 0.76 | MEN1 (0.45) | MAOATDP1 | |
| SCHEMBL6942518 | 0.73 | MAOA (0.48) | MAOAMAOBALDH1A1HPGDALOX15 | |
| SCHEMBL1463743 | 0.71 | CTBP2 (0.38) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2937880 | 0.71 | NPSR1 (0.43) | ALDH1A1HPGDTDP1SMN1; SMN2 | |
| SCHEMBL9741303 | 0.69 | ALDH1A1 (0.69) | MAOAMAOBALDH1A1HPGDALOX15 | |
| Benzene SCHEMBL3440179 | 0.69 | ALDH1A1 (0.69) | MAOAMAOBALDH1A1HPGDALOX15 | |
| SCHEMBL62125 | 0.69 | ALDH1A1 (0.69) | MAOAMAOBALDH1A1HPGDALOX15 | |
| Cyclooctane SCHEMBL18187569 | 0.67 | SIGMAR1 (0.58) | MAOAMAOBALDH1A1HPGDALOX15 | |
| SCHEMBL25403475 | 0.67 | ALDH1A1 (0.65) | MAOAMAOBALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | claimed |
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | claimed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | claimed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | claimed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| WO-2004052854-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION | 2004-04-29 | — | — | US | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| WO-2004018460-A1 | AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| EP-0728758-B1 | Dioxopyrrolo-pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | claimed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | claimed |
| EP-1218374-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2002-07-03 | — | — | EP | claimed |
| WO-2001023378-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | claimed |
| EP-1088821-A1 | Pharmaceutically active sulfonamide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | claimed |
| EP-0728758-A1 | Dioxopyrrolo-pyrrole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1996-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | MAOA 2983/4885MAOB 2599/4885ALDH1A1 3623/4885 |
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | MAOA 716/4885MAOB 610/4885ALDH1A1 3627/4885 |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | MAOA 360/4885MAOB 249/4885ALDH1A1 223/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | MAOA 2983/4885MAOB 2599/4885ALDH1A1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.